-
Alexion to Present at Upcoming Virtual Investor Conferences
Alexion to Present at Upcoming Virtual Investor Conferences
Share
BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the following upcoming investor conferences:
- Citi’s 15th Annual BioPharma Conference, taking place virtually on Thursday, September 10th, 2020 at 10:45 a.m. ET.
- Morgan Stanley’s 18th Annual Global Healthcare Conference, taking place virtually on Monday, September 14th, 2020 at 2:15 p.m. ET.
An audio webcast of the presentation will be available live. You can access the webcast at: http://ir.alexion.com. An archived version of the remarks will also be available through the Company’s website for a limited time following the conference.
[ALXN-G]
Contacts
Investors
Chris Stevo
Head of Investor Relations
(857) 338-9309
Alexion Pharmaceuticals
More News From Alexion Pharmaceuticals
Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)
BOSTON--(BUSINESS WIRE)--Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)....
Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021
BORDENTOWN, N.J. & BOSTON--(BUSINESS WIRE)--Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the EHA Congress 2021...
Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)
BOSTON--(BUSINESS WIRE)--Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)...
